Current therapy of demyelinating neuropathies.
Ruderman
M I
MI
Turkewitz
L J
LJ
D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D000328:Adult; D002607:Charcot-Marie-Tooth Disease / Q000628:therapy; D002648:Child; D002908:Chronic Disease; D003131:Combined Modality Therapy; D003711:Demyelinating Diseases / Q000150:complications / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008776:Methylprednisolone Hemisuccinate / Q000627:therapeutic use; D009369:Neoplasms / Q000150:complications; D009422:Nervous System Diseases / Q000628:therapy; D010265:Paraproteinemias / Q000628:therapy; D010956:Plasmapheresis; D011129:Polyradiculoneuropathy / Q000188:drug therapy / Q000628:therapy; D011239:Prednisolone / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D012121:Respiration, Artificial
D007166:Immunosuppressive Agents; D008776:Methylprednisolone Hemisuccinate; D000324:Adrenocorticotropic Hormone; D011239:Prednisolone; D011241:Prednisone